JP2025508042A5 - - Google Patents

Info

Publication number
JP2025508042A5
JP2025508042A5 JP2024553325A JP2024553325A JP2025508042A5 JP 2025508042 A5 JP2025508042 A5 JP 2025508042A5 JP 2024553325 A JP2024553325 A JP 2024553325A JP 2024553325 A JP2024553325 A JP 2024553325A JP 2025508042 A5 JP2025508042 A5 JP 2025508042A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
cdr
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024553325A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508042A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/056832 external-priority patent/WO2023175117A1/en
Publication of JP2025508042A publication Critical patent/JP2025508042A/ja
Publication of JP2025508042A5 publication Critical patent/JP2025508042A5/ja
Pending legal-status Critical Current

Links

JP2024553325A 2022-03-16 2023-03-16 Ｌｙｐｄ３に対する抗体 Pending JP2025508042A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22162550.2 2022-03-16
EP22162550 2022-03-16
PCT/EP2023/056832 WO2023175117A1 (en) 2022-03-16 2023-03-16 Antibodies against lypd3

Publications (2)

Publication Number Publication Date
JP2025508042A JP2025508042A (ja) 2025-03-21
JP2025508042A5 true JP2025508042A5 (https=) 2026-03-25

Family

ID=80785243

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024553325A Pending JP2025508042A (ja) 2022-03-16 2023-03-16 Ｌｙｐｄ３に対する抗体

Country Status (9)

Country Link
US (1) US20250074999A1 (https=)
EP (1) EP4493595A1 (https=)
JP (1) JP2025508042A (https=)
KR (1) KR20250021299A (https=)
CN (1) CN119421898A (https=)
AU (1) AU2023234686A1 (https=)
CA (1) CA3253998A1 (https=)
IL (1) IL315431A (https=)
WO (1) WO2023175117A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3539981A1 (en) 2006-09-10 2019-09-18 Glycotope GmbH Use of human cells of myeloid leukaemia origin for expression of antibodies
AU2010329904B2 (en) 2009-12-09 2015-07-09 Bayer Pharma Aktiengesellschaft Anti-C4.4a antibodies and uses thereof
KR20170058960A (ko) * 2014-09-09 2017-05-29 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 Agr2 및 그의 수용체 c4.4a 에 대한 차단 모노클로날 항체
LU92659B1 (en) 2015-02-23 2016-08-24 Glycotope Gmbh Glycooptimized antibody drug conjugates
AU2016249839B2 (en) * 2015-04-17 2021-09-09 Ventana Medical Systems, Inc. Antibodies, compositions, and immunohistochemistry methods for detecting C4.4a
WO2017156280A1 (en) * 2016-03-09 2017-09-14 Viba Therapeutics, Inc. Methods of treating cancer using monoclonal antibodies to agr2 and c4.4a

Similar Documents

Publication Publication Date Title
JP7425604B2 (ja) 抗ｃｔｌａ４－抗ｐｄ－１二機能性抗体、その医薬組成物および使用
JP6953612B2 (ja) チェックポイントインヒビター二重特異性抗体
CA2987118C (en) A pdl-1 antibody, pharmaceutical composition thereof and use thereof
US8034585B2 (en) Superagonistic anti-CD28 antibodies
JP2024125370A (ja) クローディン１８．２結合部分およびその利用
JP2012530496A5 (https=)
RU2019134352A (ru) Новые биспецифические антигенсвязывающие молекулы, обладающие способностью специфически связываться с cd40 и fap
JP2024056687A5 (https=)
TW202012450A (zh) 抗ｐｄ—１抗體及其用途
JP2018531219A (ja) Ｐｄ−ｌ１抗体
JP2018531219A6 (ja) Ｐｄ−ｌ１抗体
JP2018510617A5 (https=)
JP2018506277A5 (https=)
JP2022521305A (ja) 抗ｐｄ－ｌ１抗体及びその使用
Akbari et al. Design, expression and evaluation of a novel humanized single chain antibody against epidermal growth factor receptor (EGFR)
CN121263449A (zh) Cd19/cd38多特异性抗体
JP2022540610A5 (https=)
CN117396516A (zh) 抗cea抗体和使用方法
JP2025508042A5 (https=)
JP2025527160A (ja) 多重特異性抗体およびその使用
JP2025516805A (ja) 固形腫瘍を治療する方法
JP2024543828A5 (https=)
JP2023546277A5 (https=)
EP4603509A1 (en) Multifunctional recombinant antibody, and preparation method and use therefor
JP2022514148A5 (https=)